UPDATE: H.C. Wainwright & Co. Initiates Coverage on Agenus Following 4-Antibody Acquisition

In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Agenus (NASDAQ: AGEN ) with a Buy rating and $8.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Agenus with a BUY rating and a target price of